Advancing Oncology: Immune Checkpoint Inhibitors Market Research
As of early 2026, the field of immuno-oncology has transitioned from a promising frontier to a dominant pillar of cancer care. High-level research is currently centered on identifying precise biomarkers to improve patient response rates, which typically range between 20% and 40% for single-agent therapies. By utilizing advanced genomic sequencing and AI-driven data analysis, scientists are now...
0 Комментарии 0 Поделились 741 Просмотры 0 предпросмотр
Paravecmoi https://app.paravecmoi.club